Home » Blog » The Future of the ASCO Value Score Card

The Future of the ASCO Value Score Card


IP Blog | Dave Melin | January 25, 2016

BioBlog Weekly oncologyThis week in healthcare: What’s Next for the ASCO Value in Cancer Care Task Force, and the former editor of JAMA says drug pricing practices are “excessive” and unethical.

2016 Forecast Series — Lowell E. Shnipper, MD, Chair, ASCO Task Force on Value in Cancer Care

This article takes a look at the release this year of ASCO’s value scorecard and what we can expect to see in the near future from the ASCO Task Force on Value in Cancer Care in this area.

Drug Pricing Practices Unethical, Says Retired JAMA Editor

Former JAMA editor-in-chief Catherine DeAngelis, MD argued in a recent article that “drug manufacturers have disquietingly high profit margins and the industry must rein in some of their more excessive practices.”

Dana-Farber Physician to Serve as ASCO’s 2017-2018 President

ASCO recently announced that Bruce E. Johnson, chief clinical research officer and institute physician at Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School, will serve as ASCO’s president for 2017-2018.

Vice President Highlights CancerLinQ™ at World Economic Forum

Recently Vice President Joe Biden mentioned ASCO’s CancerLinQ as “one of the “major undertakings” designed to advance the pace of progress in the fight against cancer as part of his new “moonshot” initiative.”

Read New JOP Editorial on ASCO’s Efforts to Support the Cancer Journey in the Digital Era

A recently published editorial in the Journal of Oncology Practice “outlines ASCO’s efforts and successes in supporting cancer care in the digital era with its Clinical Oncology Treatment Plan and Summary (COTPS), the Interoperability Demonstration project, and development of CancerLinQ™, a learning health system for cancer.”

Cancer Moonshot — Is Now Finally the Time?

This article takes a look at Nixon’s declaration of the “War on Cancer” back in 1971 and some of the changes and steps that have taken place to make now a different time when a “cancer moonshot” might actually be possible.

What You Missed at the 2016 J.P. Morgan Healthcare Conference

This short video digs into some of the big news from the recent J.P. Morgan Healthcare Conference, including: “AbbVie’s standout guidance announcement, Johnson & Johnson’s plans for M&A, and a huge, exciting new project that’s seeking to radically transform cancer treatment as we know it.”

Five Pharma Picks for Another Volatile Year [login required]

After a sometimes unpredictable year for the pharmaceutical industry in 2015, Barron’s lists five companies to watch in 2016 (Lilly, Pfizer, Bristol-Myers, Portola and Alkermes) and predicts another challenging year for the pharma community.

Big Pharma Calls for New Incentives to Fight “Superbugs”

At the recent World Economic Forum in Davos, Switzerland, a coalition of over 80 companies (including major industry leaders like AstraZeneca, Merck, and Pfizer) released a statement calling for more incentives to fight “superbugs,” saying that “the spread of germs that can no longer be treated with common antibiotics has been “dramatic,” and that combating this growth should be a “top priority.”

Want more health care landscape updates and insights? Follow us on Twitter @innovpartners.


Topics in this Post:



Leave a Comment

Your email address will not be published. Required fields are marked *